Cerevel Therapeutics Holdings, Inc.
NASDAQ:CERE
44.96 (USD) • At close July 31, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2015 | 2014 | 2013 | 2012 | 2000 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 2.72 | 2.404 | 5.243 | 5.371 | 0 |
| Cost of Revenue
| 5.627 | 4.903 | 2.731 | 0.397 | 0 | 0 | 5.267 | 3.021 | 6.245 | 2.384 | 0 |
| Gross Profit
| -5.627 | -4.903 | -2.731 | -0.397 | 0 | 0 | -2.547 | -0.617 | -1.002 | 2.987 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | -0.936 | -0.257 | -0.191 | 0.556 | 0 |
| Reseach & Development Expenses
| 334.641 | 280.259 | 161.855 | 103.303 | 50.294 | 454.652 | 9.684 | 14.156 | 16.401 | 19.155 | 280.259 |
| General & Administrative Expenses
| 112.624 | 87.589 | 58.243 | 45.813 | 33.169 | 28.672 | 15.946 | 14.484 | 15.187 | 12.634 | 87.589 |
| Selling & Marketing Expenses
| -5.627 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 106.997 | 87.589 | 58.243 | 45.813 | 33.169 | 28.672 | 15.946 | 14.484 | 15.187 | 12.634 | 87.589 |
| Other Expenses
| 0 | 6.878 | -5.393 | -3.274 | 0.009 | 0 | 5.267 | 3.021 | 6.245 | 0 | 0 |
| Operating Expenses
| 441.638 | 367.848 | 220.098 | 149.116 | 83.463 | 465.672 | 30.897 | 31.661 | 37.833 | 31.789 | 367.848 |
| Operating Income
| -447.265 | -367.848 | -220.098 | -149.116 | -83.463 | -483.324 | -28.177 | -29.257 | -32.59 | -28.802 | -367.848 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | -10.359 | -12.17 | -6.216 | -5.363 | 0 |
| Total Other Income Expenses Net
| 14.926 | 16.497 | -5.236 | -3.05 | -44.881 | 19.688 | 0.022 | -0.063 | 0.08 | -0.605 | 16.497 |
| Income Before Tax
| -432.339 | -351.351 | -225.334 | -152.166 | -128.344 | -463.636 | -28.155 | -29.32 | -32.51 | -29.407 | -351.351 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | -10.351 | -12.196 | -6.201 | -5.475 | 0 |
| Income Tax Expense
| 0.503 | 0.16 | -2.888 | -0.024 | 0.045 | -0.161 | -0.001 | -0.001 | -0.001 | 0.003 | -0.16 |
| Net Income
| -432.842 | -351.511 | -222.446 | -152.142 | -128.389 | -463.636 | -28.156 | -29.321 | -32.511 | -29.41 | -351.511 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | -10.351 | -12.197 | -6.201 | -5.476 | 0 |
| EPS
| -2.67 | -2.32 | -1.63 | -2.07 | -1.01 | -164.94 | -1.98 | -2.06 | -2.28 | -2.07 | -0.002 |
| EPS Diluted
| -2.67 | -2.32 | -1.63 | -2.07 | -1.01 | -164.93 | -4.57 | -0.81 | -2.28 | -2.07 | -0.002 |
| EBITDA
| -441.638 | -367.848 | -220.098 | -149.116 | -36.844 | -483.248 | -27.47 | -27.737 | -30.6 | -26.788 | -367.848 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | -10.099 | -11.538 | -5.836 | -4.988 | 0 |